TY - JOUR
T1 - Potent immune modulation by medi6383, an engineered human ox40 ligand igg4p fc fusion protein
AU - Oberst, Michael D.
AU - Auge, Catherine
AU - Morris, Chad
AU - Kentner, Stacy
AU - Mulgrew, Kathy
AU - McGlinchey, Kelly
AU - Hair, James
AU - Hanabuchi, Shino
AU - Du, Qun
AU - Damschroder, Melissa
AU - Feng, Hui
AU - Eck, Steven
AU - Buss, Nicholas
AU - de Haan, Lolke
AU - Pierce, Andrew J.
AU - Park, Haesun
AU - Sylwester, Andrew
AU - Axthelm, Michael K.
AU - Picker, Louis
AU - Morris, Nicholas P.
AU - Weinberg, Andrew
AU - Hammond, Scott A.
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/5
Y1 - 2018/5
N2 - Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.
AB - Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcgRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFkB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies.
UR - https://www.scopus.com/pages/publications/85047795212
U2 - 10.1158/1535-7163.MCT-17-0200
DO - 10.1158/1535-7163.MCT-17-0200
M3 - Article
C2 - 29545330
AN - SCOPUS:85047795212
SN - 1535-7163
VL - 17
SP - 1024
EP - 1038
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 5
ER -